Detectnet™ Copper (Cu-64) DOTATATE Injection

Question:
Could you please tell us how to code RadioMedix and Curium’s new FDA-approved (September 3, 2020) radiopharmaceutical, Detectnet™ Copper Cu 64 DOTATATE injection, indicated for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients?

Answer:
Please Login as a SNMMI Member to access the answers to the Coding and Reimbursement Q&As.

The opinions referenced are those of the members of the SNMMI Coding and Reimbursement Committee and their consultants based on their coding experience. They are based on the commonly used codes in Nuclear Medicine, which are not all inclusive. Always check with your local insurance carriers as policies vary by region. The final decision for the coding of a procedure must be made by the physician considering regulations of insurance carriers and any local, state or federal laws that apply to the physicians practice. The SNMMI and its representatives disclaim any liability arising from the use of these opinions.